Click a topic below for an index of articles:

 

New-Material

Home

Donate

Alternative-Treatments

Financial or Socio-Economic Issues

Forum

Health Insurance

Hepatitis

HIV/AIDS

Institutional Issues

International Reports

Legal Concerns

Math Models or Methods to Predict Trends

Medical Issues

Our Sponsors

Occupational Concerns

Our Board

Religion and infectious diseases

State Governments

Stigma or Discrimination Issues

If you would like to submit an article to this website, email us at info@heart-intl.net for a review of this paper
info@heart-intl.net

 

any words all words
Results per page:

“The only thing necessary for these diseases to the triumph is for good people and governments to do nothing.”

  


 

 

Hepatitis C

http://www.ama-assn.org/ama/pub/category/1806.html

Hepatitis C virus (Hepatitis C Virus) infection is the most common chronic bloodborne infection in the United States. During the 1980s, an average of 242,000 new infections occurred every year. However, with the advent of new tests for Hepatitis C Virus, the annual number of new infections has declined by >80% to 36,000 by 1996. An estimated 3.9 million (1.8%) Americans have been infected with Hepatitis C Virus.   75-85% of these persons are chronically infected and may not be aware of their infection due to a lack of clinical symptoms. However, infected persons can serve as a source of transmission to others and are at risk for chronic liver disease or other Hepatitis C Virus-related chronic diseases during the first two or more decades following initial infection. 

Chronic liver disease is the tenth leading cause of death among adults in the United States, and accounts for approximately 25,000 deaths annually. It is estimated from population-based studies that 40% of chronic liver disease is Hepatitis C Virus-related, resulting in an estimated 8,000–10,000 deaths each year. Hepatitis C Virus- associated end-stage liver disease is the most frequent indication for liver transplantation among adults. Because most Hepatitis C Virus-infected persons are aged 30–49 years, the number of deaths attributable to Hepatitis C Virus-related chronic liver disease could increase substantially during the next 10–20 years as this group of infected persons reaches ages at which complications from chronic liver disease typically occur. 

  


 

Hepatitis C Virus is transmitted primarily through large or repeated direct percutaneous exposures to blood. In the United States, the relative importance of the two most common exposures associated with transmission of Hepatitis C Virus, blood transfusion and injecting-drug use, has changed over time. Blood transfusion, which accounted for a substantial proportion of Hepatitis C Virus infections acquired >15 years ago, rarely accounts for recently acquired infections although the risk is not zero. In contrast, injecting-drug use consistently has accounted for a substantial proportion of Hepatitis C Virus infections and currently accounts for 60% of Hepatitis C Virus transmission in the United States and a high proportion of infections continue to be associated with injecting-drug use. 

Finally, in order to reduce the burden of Hepatitis C Virus infection and Hepatitis C Virus-related disease in the United States, primary prevention activities to reduce the risk for contracting Hepatitis C Virus infection and secondary prevention activities to reduce the risk for liver and other chronic diseases in Hepatitis C Virus-infected persons must be implemented. These programs must be supported by the medical community and the general population.